Sugi Predict

Sugi Predict / Compounds / SCHEMBL4745548

SCHEMBL4745548

SCHEMBL4745548

CC1(N)CN([C@H]2C[C@H](O)[C@@H](CO)O2)C(=O)NC1=O

nearest known ligand 0.51

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ TK1 P04183 3/20 0.43
▸ LMNA P02545 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ ADRB1 P08588 1/20 0.43
▸ DNMT1 P26358 1/20 0.43
▸ TK2 O00142 1/20 0.42
▸ ALOX12 P18054 1/20 0.40
▸ ADRA1A P35348 1/20 0.40
▸ CYP1A2 P05177 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ BLM P54132 1/20 0.39
▸ PMP22 Q01453 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16099482 0.86 TK1 (0.44) TK1LMNASMN1; SMN2ADRB1DNMT1
SCHEMBL1583331 0.86 TK1 (0.44) TK1LMNASMN1; SMN2ADRB1DNMT1
SCHEMBL15893327 0.86 TK1 (0.44) TK1LMNASMN1; SMN2ADRB1DNMT1
SCHEMBL6025793 0.85 TK1 (0.43) TK1LMNASMN1; SMN2ADRB1DNMT1
SCHEMBL18039264 0.85 TK1 (0.43) TK1LMNASMN1; SMN2ADRB1DNMT1
SCHEMBL6025787 0.85 TK1 (0.43) TK1LMNASMN1; SMN2ADRB1DNMT1
SCHEMBL292198 0.84 LMNA (0.45) TK1LMNASMN1; SMN2ADRB1DNMT1
SCHEMBL12482651 0.84 TK1 (0.45) TK1LMNASMN1; SMN2ADRB1DNMT1
SCHEMBL3501339 0.82 TK1 (0.41) TK1LMNASMN1; SMN2ADRB1DNMT1
SCHEMBL3437046 0.82 LMNA (0.46) TK1LMNASMN1; SMN2ADRB1DNMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107109483-B Method for modifying template double-stranded polynucleotide 牛津纳米孔技术公司 2021-07-20 — — CN disclosed
WO-2008118998-A2 METHOD FOR MULTIPLEX DETECTION AND QUANTITATION OF NUCLEIC ACIDS PRIMERA BIOSYSTEMS INC. (US) 2008-10-02 — — WO disclosed
EP-1639131-A1 METHOD FOR INVESTIGATING CYTOSINE METHYLATION IN DNA SEQUENCES BY MEANS OF TRIPLEX-FORMING OLIGOMERS Epigenomics AG (DE) 2006-03-29 — — EP disclosed
WO-2004113564-A1 METHOD FOR INVESTIGATING CYTOSINE METHYLATION IN DNA SEQUENCES BY MEANS OF TRIPLEX-FORMING OLIGOMERS EPIGENOMICS AG (DE) 2004-12-29 — — WO disclosed
US-20020177695-A1 Nucleic acid probes and methods DUKE UNIVERSITY 2002-11-28 — — US disclosed
US-20020123046-A1 Automated DNA sequencing technique SMITH LLOYD M (US) 2002-09-05 — — US disclosed
US-6288221-B1 REPLACING NUCLEOSIDE WITH DIMETHOXYTRITYL, PHOSPHORAMIDITE, OR HALONUCLEOSIDE DERIVATIVE; ELECTROCHEMICAL OR PHOTOCHEMICAL DETECTION OF NUCLEIC ACID SEQUENCES DUKE UNIVERSITY 2001-09-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020177695-A1 Nucleic acid probes and methods NUDT1, NT5C3B, NT5C2 TK1 71/4885LMNA 1665/4885SMN1; SMN2 3481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.